CD38 Pathway: CD38, an ectoenzyme that increases with age, is one of the largest consumers of cellular NAD+
De speciale maagresistente capsule zorg ervoor dat Acetyl-L-Glutathion moeiteloos het maag-darm kanaal bereikt.
in patients with cirrhosis and hepatic encephalopathy (ranging from mild hepatic encephalopathy to coma) confirmed that L-carnitine supplementation significantly improved hepatic encephalopathy parameters (107111)
New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
When Metformin Remains a First-Line Choice Metformin remains the standard initial medication for type 2 diabetes because it is affordable, well-tolerated, has decades of safety data, and addresses insulin resistancethe root driver of many metabolic disorders
At Sparha, the doctors will determine the dosage and the course of the treatment depending on the requirements and expectations of the patient
